Member Info for BurtonD

“…Coinsilium certainly offers access to the further gains bitcoin may make this year, but with its investment in a range of emerging Web3 technologies, Coinsilium seems to have positioned itself to be around for some time to come…”

https://total-market-solutions.com/2024/05/coinsilium-group-ltd-2/

Lexington Gold (LEX) – Corporate – Renewal of Jelani Resources Prospecting

Right

Market Cap £19.4m Share Price 5.2p

Lexington announced yesterday the renewal of the Jelani Resources Prospecting

Right until 29 May 2026. In accordance with Lexington’s acquisition of White

Rivers Exploration (WRE), the renewal of the Jelani Resources Prospecting Right

is a milestone for the issue of 25,806,451 deferred consideration shares.

The Jelani Resource Prospecting Right is adjacent to Harmony Gold’s Target 1

Mine and is the basis for the Jelani JV (joint venture) between Lexington and

Harmony Gold. Extensive and deep underground workings at the Target Mine are

a potential launch point to exploit the 2.38M oz of gold contained in the

Measured and Indicated Jelani JV resource.

WHI View: The Prospecting Right contains significant gold resources and is a key

part of Lexington’s portfolio. The successful renewal of the Prospecting Right

ensures that Lexington can continue to pursue a tribute mining arrangement with

Harmony Gold. We still see fair value at 15.3p.

Https://news.jewellerynet.com/uploads/ebook//jna/2024/May-2024/14/

Emerald, ruby and sapphire will always epitomise affluence and refinement in the jewellery industry, with buyer enthusiasm for these premium gems staying strong amid escalating

Amid the markets’ centuries-old affinity for the so-called Big Three in the jewellery trade, there are new opportunities to be had with a younger generation of buyers developing appreciation of and love for these gems.

People are training their sights on emeralds because prices keep appreciating, which is healthy for the trade.

“…Rio Tinto is paying for everything in Rwanda. In Morocco, we have 17 assets with Silver, Gold and Copper and we may look to work with one of the majors…”

Full Article : https://total-market-solutions.com/2024/05/aterian-plc-may-2024/

Interview Only : https://youtu.be/iYGrIZkeMgk

“…We have a tonne of intrinsic inherent value right now in our Pilot Mountain project…”

Full Article link :

https://total-market-solutions.com/2024/05/golden-metal-resources-plc-may-2024/

Interview only link :

https://youtu.be/pPmh6ZBnppM

“…data has been called the new oil. This is the new oil. We will strike a lot of oil…”

https://total-market-solutions.com/2024/05/electric-guitar-plc-may-2024/

Https://ukinvestormagazine.co.uk/poolbeg-pharma-shares-jump-after-announcing-year-of-progress/

Interview -

“…Our aim is to, hopefully have already potentially possibly invested in some of the winners that are coming in the next few years…”

https://total-market-solutions.com/2024/05/coinsilium-may-2024/

Ummmmm…

Looks like #HMI back on track with the fertiliser and the REE could be the huge cherry on top for @harvestminerals 🍒

“…Despite the ongoing tightness in market prospects, there are signs of improvement in the second half of the year…”

https://www.londonstockexchange.com/news-article/HMI/kp-fertil-r-sales-update/16452782

Lots of daft rumours that BLOE are looking to raise. The Company have no plans to raise. Company also in a closed period...

Https://www.blockenergy.co.uk/wp-content/uploads/2024/05/block_energy_factsheet_may_24.pdf

Https://twitter.com/PoolbegPharma/status/1785928353549001126

The future has never been brighter for Bluejay

“…A project with this size and scale will attract the attention of the majors, of which we know at least one is particularly interested…”

https://total-market-solutions.com/2024/05/bluejay-mining-plc-may-2024/

Https://www.youtube.com/embed/zV6BzFFWAuE

They received the fully granted patent from the US Patent Office for our Immunomodulator II patent application.

The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication

https://www.londonstockexchange.com/news-article/POLB/significant-polb-001-patent-granted-in-usa/16448784

NO OFFERS. BID for millions. Ready for next move back to 4p?

"...Separately, I am delighted to share that we have secured an exclusive 12-month option agreement with Silk Road Therapeutics to acquire an orphan drug candidate, a novel topical muco-adherent formulation of Pentoxifylline (PTX) for the treatment of oral ulcers in patients suffering from Behçet's Disease for a nominal fee. The foundation of any pharma company is a strong pipeline of assets, and we believe that topical PTX could fit well into our pipeline alongside our other assets as we increase our focus on rare and orphan diseases. Under this option agreement, we will advance our due diligence process and engage with Silk Road Therapeutics to further understand the clinical pathway to approval..."

https://www.londonstockexchange.com/news-article/POLB/option-agreement-to-acquire-orphan-drug-candidate/16446501

"...Finaly, we announced the appointment of Shore Capital as our Joint Broker, with Cavendish remaining as Nomad alongside Davy as our other Joint Broker. Shore Capital acted as Nominated Adviser and Joint Broker to Amryt Pharma plc during its listing on AIM in 2016, its strategic acquisitions and its dual listing on Nasdaq, and as such, they bring valuable expertise to Poolbeg Pharma as we seek to repeat the success of Amryt Pharma. With a proven track record of working with companies in the rare and orphan disease space, Shore Capital is well positioned to support Poolbeg as it pursues a similar strategic growth trajectory to Amryt...."

https://www.londonstockexchange.com/news-article/POLB/appointment-of-joint-broker/16446562

Full year results for the year ended 31 December 2023. Clearly their disciplined approach to capital allocation has ensured that they have have maintained a robust cash position of £12.2m at year end.

https://www.londonstockexchange.com/news-article/POLB/results-for-the-year-ended-31-december-2023/16446315

Poolbeg Pharma has announced FY 2023 results to end December 2023, which positively reflect the company’s capital-efficient operating model with net cash of £12.2m being reported, significantly ahead of our expectations (2023E: £10.9m). Meaningful R&D progress whilst maintaining financial prudence means that Poolbeg enters 2024 with a strong balance sheet in absolute terms and relative to many biotech peers, with a cash runway (to fund the existing R&D pipeline) we forecast will extend into 2026. This runway could be further extended should future revenues from potential partnering or licensing deals materialise. In our view, the data package for Poolbeg’s lead pipeline asset, POLB 001, has been significantly strengthened in 2023 and with the strategic expansion of the drug into oncology we believe POLB 001 could be viewed as an attractive licensing opportunity in the eyes of potential partners.